HealthInvestor Asia Summit 2018
Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: How far can medical tourism in Asia expand?

Jacob Pope explains why medical tourism remains one of the region’s most significant industries.

Medical Tourism has been a growing industry for the past decade or so, but in its earlier days, only the affluent or upper classes had the means the travel for their health or medical needs.

But over the past decade, a new – and much more robust – type of medical tourism has taken centre stage. As healthcare infrastructure in some developing nations continues to improve, patients from more developed nations are increasingly looking to emerging economies for high-value prospects in healthcare.

There is plenty contributing to this trend. Widespread, affordable air travel is driving globalisation to new heights. At the same time, rising healthcare costs across much of the developed world make finding more affordable medical care a matter of necessity for some – even if that means travelling overseas.

While there are many medical tourism hubs around the world, a select few have emerged as the indisputable leaders in this trend. The southeast Asian region has performed particularly well in this regard, with Thailand stepping out as a medical tourism powerhouse. Singapore and Malaysia have also benefited from this trend.

Bangkok’s success as a rising medical tourism destination is a shining model of how a developing nation can cater to the healthcare needs of the world at large. Tourism on the whole is one of Thailand’s main economic drivers, weighing in third after manufacturing and the automotive industry. And while medical tourism accounts for a relatively small percentage of tourism revenue, this niche sector is posting impressive year-over-year growth rates.

Private hospitals in Thailand, which are the primary domain of medical tourists, have sustained robust, double-digit growth rates in recent years. They’ve become increasingly reliant on the industry for this very reason.

Thailand’s Kasikorn Research Centre, a think tank operated by a prominent Thai bank, recently looked into this trend. The centre found that the share of private hospital revenue supplied for foreign patients reached 27% in 2015, beating a 2011 projection by two percentage points. This year, they expect that figure to rise to 30%.

And while many of these patients hail from Australia, New Zealand, Europe and, to a lesser extent, North America, the think tank recommends looking to other markets – including the Middle East and even neighbouring Myanmar – to sustain these growth figures.

If this trend continues, Thailand could well develop into the go-to international destination for healthcare procedures. In some cases, this is occurring even to the chagrin of officials in other southeast Asian nations, where some wonder what’s stopping them from duplicating the success of Thailand, Malaysia and Singapore.

Indonesia is one such nation. Stephen Lock, head of public Affairs for Edelman, believes that Indonesian policy makers would be wise to be mindful of Thailand’s success – not to mention the role that Indonesian patients have played in it. Lock reckons that Indonesian health tourists inject well over US$1 billion per year into the Malaysian economy, with as much as 30% growth per year. This accounts for almost 5% of Indonesia’s annual healthcare spend (domestically and abroad). Capitalising on the medical tourism trend would likely bring these medical tourists back home, and attract a slice of the international market as well.

It’s worth noting that Bali has had success with medical and dental tourism, but this is the exception rather than the rule in Indonesia. Bali has a robust tourism industry in general, and the local medical tourism industry has been able to flourish because of this.

Countries keen to cash on the medical tourism movement are wise to consider where the greatest gains are possible so that early revenue can be reinvested in developing further infrastructure. For many medical tourism destinations, elective procedures offer the greatest potential.

The rationale behind this is relatively straightforward. Life-or-death medical procedures must be conducted where the patient is currently located, as time is of the essence. Pressing non-emergencies leave time for planning a visit overseas, but procedures of this nature are covered by national programmes in Australia, New Zealand and many European nations. The same cannot be said of non-essential, elective procedures.

This is why cosmetic surgery and dental operations have become so popular in southeast Asia. International patients plan discreet holidays in South-East Asia so that they can avail themselves of breast augmentation in Bali or rhinoplasty in Bangkok. Other types of cosmetic surgery in Asia – from Botox injections to teeth whitening – are also popular.

The impressive revenue streams generated by health tourism in Bangkok, Bali and elsewhere in the region have paved the way for major re-investment. As a result, southeast Asia features truly state-of-the-art medical facilities and some of the world’s highest value-for-money treatment options.

Paul McTaggart, CEO of Medical Departures, explains many of his organisation’s clients actually prefer undergoing cosmetic surgery in Thailand or Bali rather than at home in Australia or New Zealand.

“Our clients tell us that it’s more than the modern facilities or value-for-money proposition that draw them to facilities like KTOP Clinic or Phuket Plastic Surgery Institute,” he says. “We’ve heard over and again that the level of care and attention they enjoy at our partner institutions is unlike anything they would receive at home,” he added.

Jacob Pope is digital marketing director of Medical Departures.


Posted on: 25/08/2017 UTC+08:00


Life sciences company OncoSil Medical is to raise A$18.7 million (US$14.4 million) in a two tranche institutional placement and share purchase plan.
Hong Kong listed hospital services company Hua Xia Healthcare has raised HK$46 million (US$5.9 million) in a private placement. Kingston Securities managed the deal.
AK Medical Holdings, which is the largest artificial orthopaedic joint manufacturer in China, has reported a 36.3% rise in profits for the year to Rmb105.4 million (US$16.7 million) on revenues that rose 37.6% to Rmb372.7 million.
Singapore-based DocDoc, a service which enables both locals and medical tourists to find a doctor or dentist across the region, has raised US$5.45 million in Series B funding. The financing is led by Adamas Finance Asia Limited (Adam), a London listed investment company which invested US$2 million via a convertible bond offering alongside regional family offices and high net worth individuals.
The owners of Australian health imaging company Pro Medicus have sold down significant stakes in the company.
IHH Healthcare, Asia’s largest healthcare company, has acquired a 60% stake in Chengdu Shenton Health Clinic, formerly known as Sincere Chengdu Clinic, from Beijing Yizhi Zhuoxin Corporate Management Information for Rmb12 million (US$1.9 million).
Japanese home care nursing group Longlife Holdings plans to set up a fee-based nursing home in Ikeda-shi, Osaka.
Sisram Medical, a Israeli subsidiary of Shanghai Fosun Pharmaceutical, and which manufactures medical aesthetics devices, has reported an 37.2% rise in annual profits to US$11 million on revenues that were up 15.9% to US$136.9 million.


Sumit Sharma, head of health & life sciences, Asia Pacific, at Oliver Wyman, and Matt Zafra, engagement manager, health & life sciences, Oliver Wyman, look at the four themes that are going to dominate healthcare this year.
It can sometimes seem that the healthcare sector is a guaranteed money spinner for investors. It has everything going for it. Societal demands and demographics make it a sure thing, say enthusiasts. And investors have become used to the fact that everything it touches turns to gold.
Yesterday’s stock price fall for Ramsay Health Care was not entirely unexpected. Shares in Australia’s largest private hospital operator dropped 5.75% to A$63.90 (US$49.81) after it revealed distinctly unimpressive first half figures.
Susann Roth, senior social development specialist, Asian Development Bank, gives one way how health risks can be lowered at Special Economic Zones.
Nicole Hill, global director of healthcare at ALE, has a goal to make everyone and everything in healthcare connected. She explains how healthcare is entering a second wave of digitisation in Asia.
There is a simple reason why healthcare stocks on the SGX rose today. Yesterday’s budget was focused firmly on healthcare. Finance minister Heng Swee Keat announced not just an additional S$10.2 billion (US$7.8 million) for healthcare over the next year, he made clear that he was committed to the sector.
A new paper from KPMG looks at the disconnect between consumer expectations and the current healthcare experience of patients in Australia.
Gan Kim Yong, Singapore’s minister for health, explains why integrated care is important in the context of an ageing population.
my images


Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices